UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Critical care (London, England), 2004-04, Vol.8 (2), p.R82-R90

2004

Link zum Volltext

Verfügbarkeit prüfen

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

Critical care medicine, 2003-01, Vol.31 (1), p.12-19

2003

Link zum Volltext

Verfügbarkeit prüfen

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

JAMA : the journal of the American Medical Association, 2013-03, Vol.309 (11), p.1154

2013

Link zum Volltext

Verfügbarkeit prüfen

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

Critical care medicine, 2004-02, Vol.32 (2), p.332-341

2004

Link zum Volltext

Verfügbarkeit prüfen

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

Critical care (London, England), 2010-01, Vol.14 (4), p.R126-R126

2010

Link zum Volltext

Verfügbarkeit prüfen

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

Intensive care medicine, 2003-06, Vol.29 (6), p.894-903

2003

Link zum Volltext

Verfügbarkeit prüfen

Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial

Critical care (London, England), 2012-01, Vol.16 (1), p.R14-R14

2012

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock: Randomized, Double-Blind, Placebo-Controlled Phase IIb Study

Critical care medicine, 2014-03, Vol.42 (3), p.504-511

2014

Link zum Volltext

Verfügbarkeit prüfen

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis

Critical care medicine, 2005-08, Vol.33 (8), p.1741-1748

2005

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients

Therapeutic drug monitoring, 2010-12, Vol.32 (6), p.749

2010

Link zum Volltext

Verfügbarkeit prüfen

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

Journal of critical care, 2007-06, Vol.22 (2), p.142-152

2007

Link zum Volltext

Verfügbarkeit prüfen

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis

Critical care medicine, 2004-11, Vol.32 (11), p.2199-2206

2004

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin

Clinical biochemistry, 2012-07, Vol.45 (10-11), p.780-786

2012

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

Critical care medicine, 2003-01, Vol.31 (1), p.1-11

2003

Link zum Volltext

Verfügbarkeit prüfen

CURB-65, PSI, and APACHE II to Assess Mortality Risk in Patients With Severe Sepsis and Community Acquired Pneumonia in PROWESS

Journal of intensive care medicine, 2011-01, Vol.26 (1), p.34-40

2011

Link zum Volltext

Verfügbarkeit prüfen

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial

Critical care medicine, 2004-11, Vol.32 (11), p.2207-2218

2004

Link zum Volltext

Verfügbarkeit prüfen

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation

Critical care medicine, 2007-06, Vol.35 (6), p.1457-1463

2007

Link zum Volltext

Verfügbarkeit prüfen

Empirical models for dosage optimization of four β-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin

Clinical biochemistry, 2010-04, Vol.43 (6), p.589-598

2010

Link zum Volltext

Verfügbarkeit prüfen

Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis

Critical care medicine, 2004-12, Vol.32 (12), p.2385-2391

2004

Link zum Volltext

Verfügbarkeit prüfen

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification

Critical care (London, England), 2003-12, Vol.7 (6), p.445-450

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological Inhibition of Tissue Factor

Seminars in thrombosis and hemostasis, 2006-02, Vol.32 (1), p.071-076

2006

Link zum Volltext

Verfügbarkeit prüfen

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Critical care (London, England), 2008-01, Vol.12 (5), p.R117-R117

2008

Link zum Volltext

Verfügbarkeit prüfen

Drotrecogin Alfa (Activated) in Severe Sepsis

The New England journal of medicine, 2006-01, Vol.354 (1), p.94-96

Friedrich, Jan O

2006

Link zum Volltext

Verfügbarkeit prüfen

Still Puzzled by Additional Data from the PROWESS Study

Critical care medicine, 2005-09, Vol.33 (9), p.2146-2146

Schultz, Marcus J

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

PublikationsformWebseiten

ThemaPatients

ThemaSepsis - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(27)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Middle Aged
(21)
Female
(20)
Male
(20)
General & Internal Medicine
(18)
Critical Care Medicine
(17)
Sepsis - Mortality
(17)
Aged
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Recombinant Proteins - Therapeutic Use
(15)
Apache
(13)
Double-Blind Method
(13)
Protein C - Therapeutic Use
(13)
Severe Sepsis
(13)
Adult
(12)
Anti-Infective Agents - Therapeutic Use
(12)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial

Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock: Randomized, Double-Blind, Placebo-Controlled Phase IIb Study

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis

Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis

Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

CURB-65, PSI, and APACHE II to Assess Mortality Risk in Patients With Severe Sepsis and Community Acquired Pneumonia in PROWESS

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation

Empirical models for dosage optimization of four β-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin

Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification

Pharmacological Inhibition of Tissue Factor

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Drotrecogin Alfa (Activated) in Severe Sepsis

Still Puzzled by Additional Data from the PROWESS Study

Aktive Filter

Suchergebnisse filtern